Gilead develops solid tumour cell therapy with GadetaGilead has option to buy biotech if things go well Share XGilead develops solid tumour cell therapy with Gadetahttps://pharmaphorum.com/news/gilead-develops-solid-tumour-cell-therapy-with-gadeta/
Immunocore and GSK pick third cancer immunotherapy targetImmunocore, one of UK biotech’s brightest hopes, has selected a third target as part of its immuno-oncology partnership Share XImmunocore and GSK pick third cancer immunotherapy targethttps://pharmaphorum.com/news/immunocore-gsk-pick-third-cancer-immunotherapy-target/